Imaging Biometrics - AGM Statement and Business Update
IMAGING BIOMETRICS LIMITED
("IBAI" or the "Company")
(LSE: IBAI)
AGM Statement and Business Update
Imaging Biometrics Limited (LSE: IBAI) is pleased to provide this update to shareholders ahead of its Annual General Meeting being held today. The Group develops quantitative neuroimaging software and organ-on-a-chip technology for healthcare and life sciences.
IB Nimble™ 2 - Commercial Launch
The Company today announces the release of IB Nimble™ 2, a substantially upgraded version of its secure mobile and web-based platform for multidisciplinary clinical collaboration. It is available on web, iOS, and Android. It is designed to support tumour board discussions, complex disease management workflows, and emergent care settings.
The release incorporates material enhancements developed in direct response to feedback from existing clinical users. In-app DICOM (medical image format) viewing allows care teams to review imaging within the platform without switching between systems. PACS (picture archiving and communication system) synchronisation makes imaging data accessible in clinical context without local installation. The release also adds customisable roles and permissions, synchronised cross-platform experience, and reinforced cybersecurity architecture.
IB Nimble™ 2 is available immediately to both existing and prospective customers. The Board expects the release to broaden the platform's addressability to institutions not previously able to justify adoption without integrated imaging capability.
IB Nimble™ 2 forms part of the Company's broader strategy to sharpen its focus on its neuroimaging software portfolio, prioritising high-quality, commercially sustainable products, as outlined in the strategic review published in
"The ability to sync with PACS and view DICOM images within IB Nimble™ 2 fundamentally changes how clinicians and researchers collaborate. Users can now review imaging data in context, alongside colleagues, in real time - without switching between systems. That is a meaningful improvement in both efficiency and clinical decision-making."
- Dr
"IB Nimble™ 2 is the direct product of listening to the clinicians who use our platform every day. Integrated image viewing within a mobile collaboration tool removes a genuine friction point in tumour board workflows. We are pleased to deliver this to our user base and to make it available to new institutions as we continue to build on the commercial momentum established in 2025."
-
QSMetric™ - GE HealthCare Distribution
In
QSMetric™ is a patented, FDA-cleared quantitative susceptibility mapping (QSM) solution developed and validated at Weill Cornell Medicine. QSMetric™ detects and measures susceptibility-based biomarkers-particularly iron and microhemorrhages-supporting diagnosis, monitoring, and treatment planning across a range of neurological conditions including amyloid-related imaging abnormalities - hemorrhagic (ARIA-H) in patients receiving anti-amyloid Alzheimer's therapies. FDA-mandated ARIA monitoring is a protocol requirement for these treatments.
IBAI contributes its certified Quality Management System, regulatory expertise, and global support infrastructure. Integration of QSMetric™ into GE's distribution ecosystem is progressing, and the Board views this as an incremental revenue opportunity for the Group.
Kirkstall Limited - Organ-on-a-Chip Platform
Kirkstall, acquired in
The Quasi-Vivo® organ-on-a-chip platform is in active use in pharmaceutical research, toxicology, and disease modelling. A BBSRC/NC3Rs-funded collaboration with Nottingham Trent University is developing a glioblastoma tumour-on-a-chip model. This opens a route into pharmaceutical drug discovery, a segment with larger and recurring order volumes.
Kirkstall is transitioning from a university-centric business toward a commercially scalable operation. The platform is well positioned to benefit from the global regulatory shift away from animal testing, including the US FDA Modernization Act 2.0 and equivalent mandates in the
Gallium Maltolate - Phase 1 Publication
Following the successful completion of the Phase 1 clinical trial of oral gallium maltolate (GaM) in
Chief Executive's Statement
"Imaging Biometrics enters this AGM with commercial momentum that is genuine and measurable. Our neuroimaging software is now distributed by global partners. Our mobile collaboration platform has been substantially upgraded. Our organ-on-a-chip business is generating early commercial traction. With IB Nimble™ 2 launched and the enhanced IB Clinic platform nearing release, new Kirkstall distribution partners in place, and global distribution relationships expanded, the Board is confident the Group is entering a period of revenue acceleration. Our expectation of progress towards profitability in 2026 is unchanged."
-
- ENDS -
Imaging Biometrics Limited
Tel: 020 7469 0930
AlbR Capital Limited
Corporate Broker
Tel: 020 74690930
About Imaging Biometrics Limited
Imaging Biometrics Limited (LSE: IBAI) is a healthcare technology group with two principal subsidiaries. Imaging Biometrics LLC, based in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE